Effect of the serotonin antagonists ritanserin and ketanserin in Cushing’s disease
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Central serotonergic regulation could have a role in the course of pituitary-dependent Cushing's disease. We studied the effects of ritanserin and ketanserin, two related selective 5HT2 receptor antagonists, in 11 patients with Cushing's disease. Treatment lasted from 1 month to 1 year (up to 4 years in one patient). Daily doses were 10-15 mg for ritanserin, and 40-80 mg for ketanserin. Since the two drugs share the same mechanism of action and no qualitative or quantitative differences in response to their administration were observed, the results were pooled together. Patients were assessed by clinical and hormonal evaluation. Urinary cortisol and ACTH were considered the parameters of interest. Short-term response: after 1 month, there was a significant decrease of urinary cortisol from 781 (160) to 331 (215) nmol/d (P < 0.02) while ACTH was 9.8 (1.5) pmol/L baseline and again 8.8 (2.2) pmol/L at 1 month (P = NS). For 9 patients, hormonal parameters were available after 1 week of treatment. In this case, also ACTH levels were significantly decreased (from 9.6 (1.7) to 5.2 (1.3) pmol/L; P < 0.01) together with urinary cortisol (from 781 (194) to 372 (165) nmol/d; P < 0.01). Long-term response: in 3 patients, hormonal parameters failed to respond to serotonin receptor antagonists, which were thus discontinued. An improvement was recorded in the remaining 8 patients, that was prolonged in 3, and transient in 5. In 3 of these latter patients, a marked increase of ACTH was observed before treatment discontinuation. Ketanserin was given to 2 patients with Nelson's syndrome, with only transient ACTH decrease in one, and no changes in ACTH response to CRH after 1 month treatment in both cases. An inhibitory effect of ritanserin and ketanserin on ACTH and cortisol production in Cushing's disease appeared to be limited both in terms of duration of response and number of patients with a satisfactory outcome. However, the results may provide a better understanding of serotonergic modulation in Cushing's disease and lead to therapeutic developments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hence a down-regulation of 5HT2 post-synaptic receptors which has been proposed as one of the final pathways driving therapeutic effects of different antidepressant [50] may facilitate 5HT1 receptor neurotransmission, which in turn may activate the HPA axis with an increased production of adrenocorticotropic hormone (ACTH) and cortisol [51].”
Citations
Cites
International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).
Hoyer, D., Clarke, D. E., Fozard, J. R., Hartig, P. R., Martin, G. R., Mylecharane, E. J., Saxena, P. R., & Humphrey, P. P. (1994) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06783-3 · Cited by 3,003
Role of 5-HT in stress, anxiety, and depression
Graeff, F. G., Guimarães, F. S., De Andrade, T. G. C. S., & Deakin, J. F. W. (1996) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(95)02135-3 · Cited by 984 · cited 1×
“There is extensive preclinical evidence on the biphasic nature of the relationship between serotonin receptors and adrenal steroids [ 36 ].”
BackgroundLeysen, J. E., Gommeren, W., Van Gompel, P., Wynants, J., Janssen, P. F., & Laduron, P. M. (1985) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)12558-3 · Cited by 452
Cyproheptadine-Induced Remission of Cushing's Disease
Krieger, D. T., Amorosa, L., & Linick, F. (1975) · New England Journal of Medicine · doi:10.1056/nejm197510302931802 · Cited by 316 · cited 1×
“Krieger et al. [ 1 ] introduced the use of an antiserotonergic drug, cyproheptadine, in the treatment of Cushing’s disease.”
BackgroundThe Cushing Syndrome: An Update on Diagnostic Tests
Kaye, T. B., & Crapo, L. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-3-112-6-434 · Cited by 310
Serotonin and the regulation of hypothalamic-pituitary-adrenal axis function
Dinan, T. G. (1996) · Life Sciences · doi:10.1016/0024-3205(96)00066-5 · Cited by 303
Risk factors and long-term outcome in pituitary-dependent Cushing's disease
Sonino, N. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.7.2647 · Cited by 265 · cited 1×
“The differential diagnosis included high dose dexamethasone (signi~cant suppression occurred if cortisol at the end o the test had fallen to 50% or less of its basal levels) and CRH tests, and ACTH measurements [22, 23 ].”
BackgroundThe Medical Treatment of Cushing's Syndrome
MILLER, J. W., & CRAPO, L. (1993) · Endocrine Reviews · doi:10.1210/edrv-14-4-443 · Cited by 202 · cited 1×
“Variable outcomes have been also observed with other neuromodulatory agents, such as bromocriptine, valproic acid and octreotide [ 2 ,3].”
ResultKetoconazole treatment in Cushing’s syndrome: experience in 34 patients
Sonino, N., Boscaro, M., Paoletta, A., Mantero, F., & Zillotto, D. (1991) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1991.tb03547.x · Cited by 201 · cited 1×
“Combination therapies with compounds inhibiting cortisol production at adrenal level, i.e. ketoconazole [3, 37 ], are also conceivable.”
BackgroundSelf-citationCALOGERO, A. E., BAGDY, G., SZEMEREDI, K., TARTAGLIA, M. E., GOLD, P. W., & CHROUSOS, G. P. (1990) · Endocrinology · doi:10.1210/endo-126-4-1888 · Cited by 164 · cited 1×
“The use of 5HT2A and 5HT2C receptor antagonists in Cushing’s disease might lead to 5HT1A receptors activation, which in turn is likely to stimulate ACTH release [ 30 ].”
MethodPharmacological profile of ritanserin: A very specific central serotonin S2‐antagonist
Awouters, F. H. L., Niemegeers, C. J. E., Megens, A. A. H. P., Meert, T. F., & Janssen, P. A. J. (1988) · Drug Development Research · doi:10.1002/ddr.430150107 · Cited by 139
Evidence for Two Subtypes of Cushing's Disease Based on the Analysis of Episodic Cortisol Secretion
Van Cauter, E., & Refetoff, S. (1985) · New England Journal of Medicine · doi:10.1056/nejm198505233122102 · Cited by 137 · cited 1×
“Another strategy for increasing the effectiveness of serotonin receptor antagonists could pass through a better selection of the clinical population target [ 38 ].”
BackgroundSeibyl, J. P., Krystal, J. H., Price, L. H., Woods, S. W., D'Amico, C., Heninger, G. R., & Charney, D. S. (1991) · Psychiatry Research · doi:10.1016/0165-1781(91)90013-f · Cited by 104 · cited 1×
“In normal subjects it displayed an inhibitory effect on the hypothalamicpituitary-adrenal (HPA) axis by acute testing [14, 15 ].”
BackgroundMEDICAL THERAPY FOR CUSHING'S DISEASE
Sonino, N., & Boscaro, M. (1999) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70064-5 · Cited by 93 · cited 2×
“Combination therapies with compounds inhibiting cortisol production at adrenal level, i.e. ketoconazole [ 3 ,37], are also conceivable.”
BackgroundResultSerotonin receptors involved in regulation of pituitary-adrenocortical function in rats
Fuller, R. W. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00099-x · Cited by 91
Serotonin and Serotonin Antagonism in Cardiovascular and Non‐Cardiovascular Disease
Frishman, W. H., Huberfeld, S., Okin, S., Wang, Y., Kumar, A., & Shareef, B. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb05013.x · Cited by 89
van Praag, H. M. (1996) · Psychiatry Research · doi:10.1016/s0165-1781(96)02923-x · Cited by 87
Psychosomatic Aspects of Cushing’s Disease
Sonino, N., & Fava, G. A. (1998) · Psychotherapy and Psychosomatics · doi:10.1159/000012274 · Cited by 82
Serotonergic Regulation of Adrenocortical Function
Lefèbvre, H., Contesse, V., Delarue, C., Vaudry, H., & Kuhn, J. (1998) · Hormone and Metabolic Research · doi:10.1055/s-2007-978904 · Cited by 72
Souza, E. B. D. (1986) · Endocrinology · doi:10.1210/endo-119-4-1534 · Cited by 60
A role for life events in the pathogenesis of Cushing's disease
Sonino, N., Fava, G. A., & Boscaro, M. (1993) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1993.tb01004.x · Cited by 59 · cited 1×
“Serotonergic control may be involved in Cushing’s disease in a number of ways: by mediating HPA activation following stressful life circumstances [ 32 ,33]; by playing a permissive role in the clonal expansion of a mutated pituitary cell [34]: or by perpetuating a faulty cortisol/serotonin interplay [35].”
BackgroundEvidence that ACTH secretion is regulated by serotonin2A/2C (5-HT2A/2C) receptors.
Rittenhouse, P. A., Bakkum, E. A., Levy, A. D., Li, Q., Carnes, M., & van de Kar, L. D. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24053-8 · Cited by 55
Molecular modeling of serotonin, ketanserin, ritanserin and their 5-HT2C receptor interactions
Kristiansen, K., & Dahl, S. G. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00180-x · Cited by 53 · cited 1×
“Ketanserin has a much higher af~nity to 5HT2A than 5HT2C receptors [ 9 ].”
BackgroundOn a Nonparametric Combination Method for Dependent Permutation Tests with Applications
Pesarin, F. (2010) · Psychotherapy and Psychosomatics · doi:10.1159/000288391 · Cited by 47 · cited 1×
“A non parametric method, the permutation test, adapted by Pesarin [ 25 ], was used to evaluate differences in urinary cortisol, plasma cortisol and ACTH levels, before and after treatment, in the 11 patients with Cushing’s disease.”
MethodPRESCOTT, R. W. G., KENDALL‐TAYLOR, P., WEIGHTMAN, D. R., WATSON, M. J., & RATCLIFFE, W. A. (1984) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1984.tb00068.x · Cited by 36
Comparative pharmacological profile of ritanserin and ketanserin
Nueten, J. M. V., Schuurkes, J. A. J., Ridder, W. J. E. D., Kuyps, J. J. M. D., & Janssens, W. J. (1986) · Drug Development Research · doi:10.1002/ddr.430080122 · Cited by 36
Pathogenesis of Pituitary Cushing’s Syndrome: Pituitary Versus Hypothalamic
Biller, B. M. K. (1994) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30083-5 · Cited by 27
Selective Venous Sampling in the Differential Diagnosis of ACTH-Dependent Cushing’s Syndrome
Boscaro, M., Rampazzo, A., Paoletta, A., Roseano, P., Pagotto, U., Fallo, F., & Sonino, N. (2008) · Neuroendocrinology · doi:10.1159/000126124 · Cited by 26 · cited 1×
“When indicated, bilateral petrosal sinus sampling with oCRH stimulation was also employed [ 24 ].”
MethodINFLUENCE OF α1‐ADRENOCEPTOR ANTAGONISM OF KETANSERIN ON THE NATURE OF ITS 5‐HT2 RECEPTOR ANTAGONISM
Marwood, J. F. (1994) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1994.tb02657.x · Cited by 24
Serotonin 5-HT2 Receptor Antagonists: Potential in the Treatment of Psychiatric Disorders
Stefański, R., & Goldberg, S. R. (1997) · CNS Drugs · doi:10.2165/00023210-199707050-00006 · Cited by 24 · cited 2×
“It readily crosses the blood-brain barrier and as a centrally active compound has been evaluated in a variety of psychiatric disorders [ 10 ].”
BackgroundBERNINI, G. P., Argenio, G. F., Vivaldi, M. S., Corso, C. D., Birindelli, R., Luisi, M., & Franchi, F. (1990) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1990.tb00885.x · Cited by 18
Cortisol secretory patterns in Cushing's disease and response to cyproheptadine treatment
Hogervorst, C. O. V. W., Koppeschaar, H. P. F., ZELISSEN, P. M. J., Lips, C. J. M., & Garcia, B. M. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.2.8636284 · Cited by 18
Facchinetti, F., Martignoni, E., Nappi, G., Marini, S., Petraglia, F., Sandrini, G., & Genazzani, A. R. (2008) · Hormone Research · doi:10.1159/000180776 · Cited by 12
What is the cause of Cushing's disease?
Grossman, A. B. (1992) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1992.tb02244.x · Cited by 10 · cited 1×
“The role of serotonin in the development and course of Cushing’s disease is still controversial [ 5 ,6].”
BackgroundTepavčević, D., Giljević, Z., Aganović, I., Koršić, M., Halimi, S., Suchanek, E., Jelić, T., Kožić, B., & Plavšić, V. (1995) · Journal of Endocrinological Investigation · doi:10.1007/bf03349740 · Cited by 10
Potential Therapeutic Effects of Ritanserin in Cushing's Disease
Sonino, N. (1992) · JAMA · doi:10.1001/jama.1992.03480080043020 · Cited by 9 · cited 1×
“Short-term effects of ritanserin in 3 of the patients with Cushing’s disease were described in a preliminary report [ 21 ].”
BackgroundFiekers, J. F., & Konopka, L. M. (1994) · Life Sciences · doi:10.1016/0024-3205(94)90077-9 · Cited by 8
Cohen, M. L., Bloomquist, W., Snoddy, H. D., & Fuller, R. W. (1989) · Life Sciences · doi:10.1016/0024-3205(89)90507-9 · Cited by 7
Falaschi, P., Rosa, M., Rocco, A., D’URSO, R., Proletti, A., & Melts, G. B. (1991) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1991.tb00324.x · Cited by 3
Cited by
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement
Biller, B. M. K., Grossman, A. B., Stewart, P. M., Melmed, S., Bertagna, X., Bertherat, J., Buchfelder, M., Colao, A., Hermus, A. R., Hofland, L. J., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2734 · Cited by 853
“-aminobutyric acid (GABA) agonists are generally ineffective and are not routinely recommended (86).”
BackgroundSelf-citationThe Treatment of Cushing's Disease
Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 465
Boscaro, M., Barzon, L., Fallo, F., & Sonino, N. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04172-6 · Cited by 350
Sonino, N., & Fava, G. A. (2001) · CNS Drugs · doi:10.2165/00023210-200115050-00003 · Cited by 267
Metadata
- Authors
- Sonino, N., Fava, G. A., Fallo, F., Franceschetto, A., Belluardo, P., & Boscaro, M.
- Affiliations
- University of Padua (IT)
- University at Buffalo, State University of New York (US)
- Venue
- Pituitary
- Published
- 2000-10
- Volume
- 3
- Issue
- 2
- Pages
- 55-59
- ISSN
- 1386-341X (ISSN-L)
- 1573-7403
- OpenAlex
- W130491512
- Cited by
- 41
- References
- 39
- Citations by year
- 2023: 1 · 2022: 1 · 2020: 1 · 2018: 4 · 2017: 1 · 2016: 2 · 2015: 4 · 2013: 2
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Pituitary (publishedVersion)
- PubMed (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Nephrology › Electrolyte and hormonal disorders
- Keywords
- Cushing's disease, ritanserin, ketanserin, 5-HT2 receptor antagonist, serotonin, ACTH, urinary cortisol, Nelson's syndrome, serotonergic regulation, pituitary-dependent Cushing's disease, drug response
- MeSH terms
- Adolescent, Adrenocorticotropic Hormone, Adult, Cushing Syndrome, Female, Hormones, Humans, Hydrocortisone, Ketanserin, Long-Term Care, Male, Middle Aged, Nelson Syndrome, Serotonin Antagonists, Ritanserin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.